Sun Pharmaceutical Industries on Monday mentioned its consolidated internet loss stood at ₹2,277 crore for the fourth quarter ended March 2022, primarily on account of a one-time distinctive loss.
The Mumbai-based drug main had reported a internet revenue of ₹894 crore within the January-March interval of 2020-21.
Consolidated gross sales from operations stood at ₹9,386 crore within the fourth quarter.
The firm had reported gross sales from operations at ₹8,464 crore within the year-ago interval.
During the interval below evaluate, the corporate mentioned it incurred a one-time price of ₹56.35 crore for restructuring operations in sure nations.
Total loss cited as an distinctive merchandise in the course of the fourth quarter, stood at ₹3,936 crore.
For the yr ended March 2022, the corporate reported a consolidated internet revenue of ₹3,273 crore. The identical stood at ₹2,904 crore in FY21.
Revenues from operations stood at ₹38,426 crore within the final fiscal. It was ₹33,233 crore in 2020-21.
During the quarter and yr ended March 2022, the corporate mentioned its unit Taro Pharmaceutical Industries has acquired Alchemee, previously The Proactiv Company (TPC), from Galderma.
Accordingly, the outcomes for the quarter and yr ended March 2022 will not be corresponding to the sooner durations introduced, it added.
Sun Pharma Managing Director Dilip Shanghvi mentioned: “FY22 was a good year with strong topline and EBITDA growth. All our geographies have recorded double-digit growth and profitability has improved despite rising costs”.
The speciality enterprise continues to ramp up strongly, with world Ilumya gross sales recording 81% progress to succeed in ₹315 million in FY22, he added.
“Our India business continues to grow faster than the market, leading to an increase in market share. We continue to focus on expanding our global speciality business, growing all our businesses and improving operational efficiencies,” Mr. Shanghvi said.
The firm mentioned its board has proposed a closing dividend of ₹3 per share for FY22.
This is along with the interim dividend of ₹7 per share paid in FY22, taking the whole dividend for FY22 to ₹10 per share in comparison with ₹7.5 per share for FY21.
The firm’s board additionally authorised the re-appointment of Dilip Shanghvi because the Managing Director for an extra time period of 5 years with impact from April 1, 2023, as much as March 31, 2028, topic to the approval of the shareholders.
The board additionally appointed Pawan Goenka because the Lead Independent Director with rapid impact.
Shares of the corporate ended 1.75% down at ₹888.10 apiece on the BSE.
Source: www.thehindu.com
